New Treatments Target Faulty Genetic Heart Signals

(Posted on Wednesday, March 25, 2026)

A new genetic blood test helps families move from uncertainty to clearer answers about why a child is born with a serious heart defect, and that clarity now shapes the next wave of targeted treatments in development. For parents who leave the hospital after major infant heart surgery with no explanation for what went wrong, this test offers something rare. It provides a way to connect a specific gene change to their child’s condition and to future options. It also marks the beginning of a new era, in which congenital heart disease care shifts from focusing solely on anatomy to addressing underlying biology.

Genetic Test Reads DNA Tags to Clarify Heart Risk

Every cell in the body carries genes. These are the instruction manuals that tell cells how to build and run each organ. When a gene that helps guide heart development carries a change, those altered instructions can sometimes nudge the developing heart off course. This leads to a structural defect.

One of the key genes involved in this process is NOTCH1. The gene tells the body how to make a protein that sits on the surface of cells. The protein is similar to a traffic controller. It helps early heart cells decide when to grow, divide and specialize. During fetal life, this protein is especially important for shaping the heart valves, growing blood vessels and building the pathway that lets blood leave the heart for the rest of the body.

Traditional genetic tests identify rare NOTCH1 gene changes. Many of these are classified as variants of uncertain significance. The new test measures DNA methylation, chemical tags that indicate how a cell uses a gene, also known as an episignature. In the study, DNA from dozens of people with rare variants was examined using a test that scanned more than 740,000 sites across the genome. A pattern was found: if the episignature matches, it’s likely the change causes disease. If there’s no pattern, the change is likely harmless, though a negative result doesn’t fully rule out a genetic cause.

Results Help Plan Care And Understand Future Risk

These results provide clear diagnostic information. A confirmed NOTCH1 diagnosis explains the cause of a heart defect, guides clinical care and informs future decisions. Identifying a disease-causing variant indicates a hereditary component. Therefore, siblings and parents may also benefit from heart imaging or genetic testing. This information can be crucial as early detection of valve or aortic changes enables treatment before symptoms or complications arise.

Identifying the specific NOTCH1 mutation also helps estimate the risk of recurrence in future pregnancies. The test results support targeted prenatal scans, early heart evaluations, or fetal genetic testing to reduce risk. Clear genetic answers also inform consideration of emerging treatments and ongoing research for NOTCH1-related heart conditions.

Evolving Approaches to Treatment After Testing

Current treatments for NOTCH1-related heart disease address structural and functional abnormalities through surgery and drugs. These treatments repair or bypass malformed valves and vessels, and control heart rhythm, blood pressure and fluid balance. The interventions manage disease consequences but do not correct changes in the signaling pathway. The pathway enables cell communication and directs growth, division and specialization.

NOTCH signaling occurs in many tissues. Developing drugs that target this pathway without affecting other organs is complex. New approaches use small-molecule drugs, antibodies or peptide therapies to selectively modulate the pathway in the heart. Experimental treatments also target small RNA molecules that regulate gene expression and influence blood vessel growth and heart muscle cell development. Modulating these may enable more personalized treatment strategies for cardiovascular disease.

Other tools adjust gene function by changing chemical marks on DNA or related proteins, a process called epigenetic regulation. These methods fine-tune heart-related genes in a controlled, reversible manner, rather than permanently altering the DNA sequence. Combining targeted therapies with gene and epigenetic tools could yield more precise treatments with fewer side effects than many traditional drugs. Most of these approaches remain in preclinical or early clinical testing.

A Bridge From Uncertainty to Innovation

This new genetic test represents a significant advance, providing families with answers about the causes of congenital heart defects. It connects diagnostic clarity to the development of future individualized treatments. My book, Destiny’s Child No Longer: Rewriting Genetic Fate, explores this same idea by showing how the power to read and rewrite genes reshapes lives and clinical practice. By addressing the underlying biology, these advances support care that meets both clinical and patient needs. As research progresses and therapies become more precise, genetic testing will play a central role in advancing care for congenital heart disease.

Back to Writings

Read Dr. Haseltine's latest piece with